{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:53:36Z","timestamp":1792079616212,"version":"4.4.0"},"reference-count":97,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Sarcomas are a heterogeneous group of malignancies with limited therapeutic options, particularly in the metastatic setting. Adoptive cellular therapies (ACTs), including tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor (CAR) T-cell therapy, and T-cell receptor (TCR) gene-modified T-cell therapy, offer promising novel approaches for these refractory tumors. TIL-based therapy has demonstrated early efficacy in melanoma and myeloma, with ongoing trials exploring its role in sarcoma. CAR T-cell strategies targeting HER2, GD2, and B7-H3 antigens are in development, though challenges such as tumor microenvironment-mediated resistance and antigen escape remain significant. Engineered TCRs, particularly those targeting MAGE-A4 and NY-ESO-1, have shown promising clinical results in synovial sarcoma (SS) and myxoid\/round cell liposarcoma (MRCLS), leading to the recent FDA approval of afamitresgene autoleucel (afami-cel) and letetresgene autoleucel (lete-cel). Despite encouraging preliminary data, ACT implementation faces barriers including limited antigen specificity, off-tumor toxicity, immune evasion, and manufacturing scalability. Future research will focus on optimizing lymphodepleting regimens, mitigating toxicity, enhancing in vivo persistence, and combining ACT with other therapeutic agents. As clinical trials expand, ACT holds the potential to revolutionize sarcoma treatment by offering durable, targeted therapies for previously refractory disease.<\/jats:p>","DOI":"10.3390\/cancers17081302","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T03:39:16Z","timestamp":1744601956000},"page":"1302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Review of Adoptive Cellular Therapies for the Treatment of Sarcoma"],"prefix":"10.3390","volume":"17","author":[{"given":"James J.","family":"Fradin","sequence":"first","affiliation":[{"name":"Division of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-0029","authenticated-orcid":false,"given":"John A.","family":"Charlson","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO Classification of Soft Tissue Tumours: News and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/cncr.25538","article-title":"Trends in survival for patients with metastatic soft-tissue sarcoma","volume":"117","author":"Italiano","year":"2011","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1159\/000509519","article-title":"Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years","volume":"43","author":"Lochner","year":"2020","journal-title":"Oncol. Res. Treat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1002\/cncr.34370","article-title":"Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study","volume":"128","author":"Ravi","year":"2022","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for advanced alveolar soft part sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"328","article-title":"Immune checkpoint inhibitor resistance in soft tissue sarcoma","volume":"5","author":"Eulo","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14712598.2022.2064711","article-title":"Tumor-infiltrating lymphocytes for adoptive cell therapy: Recent advances, challenges, and future directions","volume":"22","author":"Presti","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ko, A., Coward, V.S., Gokgoz, N., Dickson, B.C., Tsoi, K., Wunder, J.S., and Andrulis, I.L. (2022). Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma. Cancers, 14.","DOI":"10.3390\/cancers14030548"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/CJI.0000000000000355","article-title":"Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function","volume":"44","author":"Mullinax","year":"2021","journal-title":"J. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2290900","DOI":"10.1080\/2162402X.2023.2290900","article-title":"LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma","volume":"13","author":"Nielsen","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-20-3435","article-title":"Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors","volume":"27","author":"Spicer","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","article-title":"The promise and potential pitfalls of chimeric antigen receptors","volume":"21","author":"Sadelain","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ejca.2005.03.015","article-title":"Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing\u2019s sarcoma","volume":"41","author":"Scotlandi","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: A report from the children\u2019s oncology group","volume":"30","author":"Ebb","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11527","DOI":"10.1200\/JCO.2023.41.16_suppl.11527","article-title":"PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A children\u2019s oncology group pediatric early-phase clinical Trial Network study","volume":"41","author":"Reed","year":"2023","journal-title":"JCO"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: Genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: A phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00262-024-03642-4","article-title":"Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity","volume":"73","author":"Cao","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., and Zhang, Y. (2013). B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070689"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Qin, D., Shou, A.C., Liu, Y., Wang, Y., and Zhou, L. (2023). Exploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies. J. Clin. Med., 12.","DOI":"10.3390\/jcm12196124"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/s41417-024-00823-2","article-title":"FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma","volume":"31","author":"Xiao","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gargett, T., and Brown, M.P. (2014). The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front. Pharmacol., 5.","DOI":"10.3389\/fphar.2014.00235"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): An international, open-label, phase 2 trial","volume":"403","author":"Araujo","year":"2024","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1682381","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.21037\/atm-20-6041","article-title":"Turning \u201cCold\u201d tumors \u201cHot\u201d: Immunotherapies in sarcoma","volume":"9","author":"Rytlewski","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1002\/cncr.30726","article-title":"T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas","volume":"123","author":"Pollack","year":"2017","journal-title":"Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","article-title":"Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1","volume":"61","author":"Iura","year":"2017","journal-title":"Hum. Pathol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Daudi, S., Eng, K.H., Mhawech-Fauceglia, P., Morrison, C., Miliotto, A., Beck, A., Matsuzaki, J., Tsuji, T., Groman, A., and Gnjatic, S. (2014). Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104099"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: A phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2014.155","article-title":"NY-ESO-1 (CTAG1B) expression in mesenchymal tumors","volume":"28","author":"Endo","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4161\/onci.21059","article-title":"NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target","volume":"1","author":"Lai","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma","volume":"8","author":"Melchiori","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","article-title":"Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma","volume":"13","author":"Gyurdieva","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1111\/cas.13769","article-title":"Prognostic impact of the tumor immune microenvironment in synovial sarcoma","volume":"109","author":"Oike","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2024.42.16_suppl.2500","article-title":"Lete-cel in patients with synovial sarcoma or myxoid\/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial","volume":"42","author":"Furness","year":"2024","journal-title":"JCO"},{"key":"ref_45","unstructured":"(2025, January 12). Adaptimmune\u2019s Lete-cel Achieves Primary Endpoint in Pivotal Trial :: Adaptimmune (ADAP). Available online: https:\/\/www.adaptimmune.com\/investors-and-media\/news-center\/press-releases\/detail\/277\/adaptimmunes-lete-cel-achieves-primary-endpoint-in-pivotal."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, S.P., Druta, M., Van Tine, B.A., Liebner, D., Schuetze, S.M., Tap, W.D., Preston, J., Goodison, S., D\u2019Souza, J.W., and Kapoor, G.S. (2025). Letetresgene autoleucel in advanced\/metastatic myxoid\/round cell liposarcoma. J. Clin. Oncol., 1\u201312.","DOI":"10.1200\/JCO-24-01466"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.34453","article-title":"A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma","volume":"152","author":"Ishihara","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9209","DOI":"10.1021\/nn502975r","article-title":"Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity","volume":"8","author":"Muraoka","year":"2014","journal-title":"ACS Nano"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1479-5876-11-246","article-title":"Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients","volume":"11","author":"Kageyama","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1016\/j.annonc.2021.08.1062","article-title":"540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8\u03b1 co-receptor and an affinity optimized TCR targeting MAGE-A4","volume":"32","author":"Hong","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Albarr\u00e1n, V., Villamayor, M.L., Pozas, J., Chamorro, J., Rosero, D.I., San Rom\u00e1n, M., Guerrero, P., P\u00e9rez de Aguado, P., Calvo, J.C., and Garc\u00eda de Quevedo, C. (2023). Current landscape of immunotherapy for advanced sarcoma. Cancers, 15.","DOI":"10.3389\/fimmu.2024.1352805"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Recine, F., Vanni, S., Bongiovanni, A., Fausti, V., Mercatali, L., Miserocchi, G., Liverani, C., Pieri, F., Casadei, R., and Cavaliere, D. (2024). Clinical and translational implications of immunotherapy in sarcomas. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1378398"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e432234","DOI":"10.1200\/EDBK_432234","article-title":"Immunotherapy in sarcoma: Current data and promising strategies","volume":"44","author":"Wood","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/intimm\/dxy042","article-title":"Immune suppression and reversal of the suppressive tumor microenvironment","volume":"30","author":"Shimizu","year":"2018","journal-title":"Int. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Fujiwara, T., Healey, J., Ogura, K., Yoshida, A., Kondo, H., Hata, T., Kure, M., Tazawa, H., Nakata, E., and Kunisada, T. (2021). Role of Tumor-Associated Macrophages in Sarcomas. Cancers, 13.","DOI":"10.3390\/cancers13051086"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1331193","DOI":"10.1080\/2162402X.2017.1331193","article-title":"CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial","volume":"6","author":"Illac","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"78343","DOI":"10.18632\/oncotarget.13055","article-title":"Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma","volume":"7","author":"Dumars","year":"2016","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"101703","DOI":"10.1016\/j.smim.2022.101703","article-title":"Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?","volume":"65","author":"Fridman","year":"2023","journal-title":"Semin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sorbye, S.W., Kilvaer, T., Valkov, A., Donnem, T., Smeland, E., Al-Shibli, K., Bremnes, R.M., and Busund, L.-T. (2011). Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014611"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Weng, W., Yu, L., Li, Z., Tan, C., Lv, J., Lao, I.W., Hu, W., Deng, Z., Liu, Z., and Wang, J. (2022). The immune subtypes and landscape of sarcomas. BMC Immunol., 23.","DOI":"10.1186\/s12865-022-00522-3"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"TPS11594","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS11594","article-title":"A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes","volume":"40","author":"Somaiah","year":"2022","journal-title":"JCO"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36401\/JIPO-20-32","article-title":"Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors","volume":"4","author":"Lin","year":"2021","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.1200\/JCO.2023.41.16_suppl.11508","article-title":"Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort","volume":"41","author":"Movva","year":"2023","journal-title":"JCO"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Poh, A.R., and Ernst, M. (2018). Targeting macrophages in cancer: From bench to bedside. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00049"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10555-021-09964-4","article-title":"MHC heterogeneity and response of metastases to immunotherapy","volume":"40","author":"Algarra","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40259-019-00368-z","article-title":"Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies","volume":"33","author":"Springuel","year":"2019","journal-title":"BioDrugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/cr.2016.154","article-title":"Driving gene-engineered T cell immunotherapy of cancer","volume":"27","author":"Johnson","year":"2017","journal-title":"Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","article-title":"Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: Lessons learned and strategies for moving forward","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gumber, D., and Wang, L.D. (2022). Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion. EBioMedicine, 77.","DOI":"10.1016\/j.ebiom.2022.103941"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E., Petukhov, A., Miftakhova, R., Bulatov, E., and Rizvanov, A. (2020). Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment. Cancers, 12.","DOI":"10.3390\/cancers12010125"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Janelle, V., and Delisle, J.-S. (2021). T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers, 13.","DOI":"10.3390\/cancers13040598"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm.4233","article-title":"Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system","volume":"23","author":"Workman","year":"2017","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Zhang, B., Wu, J., Jiang, H., and Zhou, M. (2025). Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. Cells, 14.","DOI":"10.3390\/cells14050320"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J. Immunother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 Increases Efficacy of CAR-T Cells in Solid Tumors without Requiring Preconditioned Lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/liv.14771","article-title":"Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro","volume":"41","author":"Xiong","year":"2021","journal-title":"Liver Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e000210","DOI":"10.1136\/jitc-2019-000210","article-title":"Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Qu, C., Zou, R., Wang, P., Zhu, Q., Kang, L., Ping, N., Xia, F., Liu, H., Kong, D., and Yu, L. (2022). Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.969660"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"eaaz1863","DOI":"10.1126\/scitranslmed.aaz1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e002755","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"\u201cFinal common pathway\u201d of human cancer immunotherapy: Targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Garcia-Garijo, A., Fajardo, C.A., and Gros, A. (2019). Determinants for neoantigen identification. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01392"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/8\/1302\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:19Z","timestamp":1760029999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/8\/1302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":97,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17081302"],"URL":"https:\/\/doi.org\/10.3390\/cancers17081302","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]}}}